Osteoporosis
15 competing products in clinical development for Osteoporosis.
Pipeline by Phase
Pre-clinical1
Phase 11
Phase 23
Phase 2/31
Phase 36
Approved3
All Products (15)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| raloxifene + placebo | Eli Lilly | Approved | Completed | 43 |
| MENATETRANONE | Eisai | Approved | Completed | 43 |
| Menatetrenone (Vitamin K2) | Eisai | Approved | Completed | 43 |
| Teriparatide + Alendronate Sodium + Placebo + Placebo | Eli Lilly | Phase 3 | Completed | 40 |
| Teriparatide | Eli Lilly | Phase 3 | Completed | 40 |
| Teriparatide + Salmon Calcitonin | Eli Lilly | Phase 3 | Completed | 40 |
| ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placebo | Chugai Pharmaceutical | Phase 3 | Completed | 40 |
| Denosumab + Placebo + Alendronate sodium hydrate | Daiichi Sankyo | Phase 3 | Completed | 40 |
| phylloquinone (K1) + menatetranone (MK4) | Eisai | Phase 3 | Completed | 40 |
| YM529 / ONO-5920 | Astellas Pharma | Phase 2/3 | Completed | 38 |
| Subcutaneous Teriparatide + Transdermal Teriparatide | Eli Lilly | Phase 2 | Completed | 35 |
| arzoxifene + Placebo | Eli Lilly | Phase 2 | Completed | 35 |
| ONO-5334 + ONO-5334 + ONO-5334 + ONO-5334 + ONO-5334 | Ono Pharmaceutical | Phase 2 | Completed | 35 |
| ONO-5920 / YM529 | Astellas Pharma | Phase 1 | Completed | 29 |
| Forteo | Eli Lilly | Pre-clinical | UNKNOWN | 22 |